Data / Form D filings / Autolus Therapeutics plc
Autolus Therapeutics plc: Form D filing
Autolus Therapeutics plc, a company in London, United Kingdom, filed a Form D with the SEC in 2024. The latest, on February 23, 2024, reports $200 million sold of a $200 million offering to 1 investor.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- c/o MediaWorks, 191 Wood Lane, London, United Kingdom, W12 7
- Phone
- (44) 20 3829 6230
- Industry
- Other
- Entity type
- Other (Public Limited Company)
- Incorporated in
- United Kingdom
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1730463
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Feb 23, 2024 | New notice | $200,000,000 | $200,000,000 | 1 | Feb 13, 2024 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Christian Itin | Executive Officer, Director | |
| William D. Young | Director | |
| Edgar Braendle | Executive Officer | |
| Martin H. Murphy | Director | |
| Linda H. Bain | Director | |
| Christopher Vann | Executive Officer | |
| Martin Pule | Executive Officer | |
| Cynthia H. Butitta | Director | |
| Robert H. Azelby | Director | |
| David Brochu | Executive Officer | |
| Joseph H. Anderson | Director | |
| Robert H. Iannone | Director | |
| John H. Berriman | Director | |
| John H. Johnson | Director | |
| Elisabeth H. Leiderman | Director | |
| Brent Rice | Executive Officer | |
| Robert Dolski | Executive Officer |
Every Form D from the week of Feb 19, 2024 · All recent Other filings
Read from SEC EDGAR. Amount sold is what Autolus Therapeutics plc reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.